WEIGHT & METABOLIC RESEARCH
Studied specifically for reducing deep abdominal fat—the kind that surrounds the internal organs.
Tesamorelin prompts the body to release its own growth hormone, and has been studied specifically for reducing visceral fat—the deep abdominal fat that surrounds internal organs and is strongly linked to insulin resistance and cardiovascular risk. It is FDA-approved for a specific clinical indication (HIV-associated lipodystrophy).
Included because it is FDA-approved (for a specific indication), works through a well-characterized GHRH-receptor mechanism, and has a defined clinical track record. It represents targeted, established metabolic research rather than broad weight-loss marketing.
Binds the receptors on the pituitary gland that trigger the body's own release of growth hormone and IGF-1, its main downstream signal.
Preferentially targets deep abdominal fat stores while, in studies, not reducing fat under the skin or muscle mass.
WHAT THE RESEARCH MEASURED
Findings describe study outcomes, not expected personal results.
Tesamorelin is FDA-approved for a specific clinical indication (HIV-associated lipodystrophy) and is not approved for general weight loss. Material offered here is sold and offered strictly for laboratory and research use.
